PubRank

Lyndsay N Harris

Author PubWeight™ 82.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 13.81
2 Molecular definition of breast tumor heterogeneity. Cancer Cell 2007 12.67
3 A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006 7.16
4 Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008 3.95
5 Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006 2.92
6 Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 2006 2.53
7 HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010 2.49
8 Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 2013 2.15
9 A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 2005 2.12
10 Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005 2.09
11 Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009 1.98
12 Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003 1.96
13 Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 2011 1.94
14 Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003 1.86
15 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004 1.83
16 Biologic, demographic, and social factors affecting triple negative breast cancer outcomes. Clin J Oncol Nurs 2015 1.39
17 VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008 1.27
18 C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011 1.21
19 Global variation in CYP2C8-CYP2C9 functional haplotypes. Pharmacogenomics J 2009 1.09
20 Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 2008 1.07
21 Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res 2011 1.07
22 Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 2009 1.02
23 The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002 0.98
24 HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 2004 0.97
25 Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res 2006 0.96
26 Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer 2008 0.94
27 Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer 2014 0.91
28 Translating next generation sequencing to practice: opportunities and necessary steps. Mol Oncol 2013 0.91
29 Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer 2012 0.88
30 Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PLoS One 2013 0.88
31 Molecular predictors of response to therapy for breast cancer. Cancer J 2011 0.88
32 Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res 2011 0.86
33 Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J Hematol Oncol 2008 0.85
34 Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res 2013 0.82
35 Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. Breast Cancer Res 2010 0.81
36 Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma. Arch Pathol Lab Med 2015 0.79
37 The renaissance of endocrine therapy in breast cancer. Curr Opin Obstet Gynecol 2014 0.78
38 Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer. Breast Cancer Res Treat 2015 0.78
39 Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers 2009 0.77
40 Genomic analysis from tissue core biopsies: standard of care for the future? Breast Cancer Res Treat 2009 0.75
41 DTCs/CTCs in breast cancer: five decades later. Recent Results Cancer Res 2012 0.75